Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery
Authors:
- Mirna B. PodollMPMirna B. Podoll
- Emily S. ReisenbichlerEREmily S. Reisenbichler
- Lania RolandLRLania Roland
- Andrew BrunerABAndrew Bruner
- Sarah MizuguchiSMSarah Mizuguchi
- Mary Ann G. SandersMSMary Ann G. Sanders
- 27 March 2018
- journal article
- review article
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 142 (9) , 1120-1126
Abstract
Context.—: Ductal carcinoma in situ (DCIS) represents 20% of screen-detected breast cancers. The likelihood that certain types of DCIS are slow growing and may never progress to invasion suggests that our current standards of treating DCIS could result in overtreatment. The LORIS (LOw RISk DCIS) and LORD (LOw Risk DCIS) trials address these concerns by randomizing patients with low-risk DCIS to either active surveillance or conventional treatment. Objective.—: To determine the upgrade rate of DCIS diagnosed on core needle biopsy to invasive carcinoma at surgery and to evaluate the safety of managing low-risk DCIS with surveillance alone, by characterizing the pathologic and clinical features of upgraded cases and applying criteria of the LORD and LORIS trials to these cases. Design.—: A 10-year retrospective analysis of DCIS on core needle biopsy with subsequent surgery. Results.—: We identified 1271 cases of DCIS on core needle biopsy: 200 (16%) low grade, 649 (51%) intermediate grade, and 422 (33%) high grade. Of the 1271 cases, we found an 8% upgrade rate to invasive carcinoma (n = 105). Nineteen of the 105 upgraded cases (18%) had positive lymph nodes. Low-grade DCIS was least likely to upgrade to invasion, comprising 10% (10 of 105) of upgraded cases. Three of the 105 upgraded cases (3%) met criteria for the LORD trial, and all were low-grade DCIS on core needle biopsy with favorable biology on follow-up. Conclusions.—: There is a clear risk of upgrade to invasion on follow-up excision; however, applying strict criteria of the LORD trial effectively decreases the likelihood of a missed invasive component or missed aggressive pathologic features.Keywords
This publication has 19 references indexed in Scilit:
- Ductal carcinoma in situ: Is core needle biopsy ever enough?Journal of Medical Imaging and Radiation Oncology, 2016
- Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?Annals of Surgical Oncology, 2016
- Rethinking the Standard for Ductal Carcinoma In Situ TreatmentJAMA Oncology, 2015
- Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In SituJAMA Oncology, 2015
- Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: A comparison between patients with and without HER2/neu overexpressionEuropean Journal of Radiology, 2014
- Concordance between vacuum assisted biopsy and postoperative histology: Implications for the proposed Low Risk DCIS Trial (LORIS)European Journal of Surgical Oncology, 2013
- Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focusJournal of Surgical Oncology, 2008
- Accuracy and Underestimation of Malignancy of Breast Core Needle Biopsy: the Florence Experience of Over 4000 Consecutive BiopsiesBreast Cancer Research and Treatment, 2006
- Mammographic size of ductal carcinoma in situ does not predict the presence of an invasive focusEuropean Journal of Cancer, 2001
- Percutaneous large-core breast biopsy: a multi-institutional study.Radiology, 1994